In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

AZ to pay £567mm for Cambridge Antibody Technology

Executive Summary

AstraZeneca has offered to pay £13.20 ($24.96) per share (a 72% premium to the market average) to buy the remaining 80% of Cambridge Antibody Technology Group PLC that it does not already own. It is effectively paying £567mm for the remaining stake, and valuing all of CAT at £702mm, about 4 times the company's 2005 revenues of £194mm.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies